Company Information
Industry 制造业
Company Introduction 上海现代制药股份有限公司(以下简称”国药现代”)成立于1996年,是由中国工程院院土创立的专业从事医药产品研发、生产、销售的医药行业高新技术企业。公司于2004年6月16日在上海证券交易所上市(代码:600420,简称:国药现代)。2010年4月进入中国医药集团有限公司(以下简称“国药集团”)。 国药现代全面服务于“健康中国”国家战略,以实现创新驱动、可持续发展、做强做优做大国有资本为发展目标,以提高企业核心竞争力和增强核心功能为努力方向,秉持国药集团“关爱生命、呵护健康”的企业理念,聚焦“抗感染、心血管、麻醉及精神、代谢及内分泌、抗肿瘤及免疫调节、大健康”六大领域,以多轮驱动实现健康、稳定和高质量发展,致力于成为创新驱动型、中国领先、国际一流的制药企业,做有活力、有实力、有影响力的行业引领者。 国药现代定位为国药集团旗下统-的化学制药工业平台,现有全资及控股子公司22家,其中二级子公司15家,三级子公司7家。形成了战略统一、资源集中、配置合理、具有规模效应及产业链联动效应的专业化战略发展格局,主营业务收入过百亿。
Main Business 医药中间体和原料药以及新型制剂类药物的研发、生产和销售
Legal Representative 许继辉
Top Executives
董事长:许继辉
董事:邢永刚,祝林,刘勇
独立董事:吴范宏,储文功,李颖琦
Top 5 Shareholder
Shareholder name Nature Holding Date
上海医药工业研究院有限公司流通A股17.86%30/06/2025
中国医药投资有限公司流通A股12.97%30/06/2025
国药集团一致药业股份有限公司流通A股12.46%30/06/2025
中国医药集团有限公司流通A股11.41%30/06/2025
张永良流通A股1.44%30/06/2025
Company Secretary 张忠喜
Solicitors 国浩律师(北京)事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 021-52372865
Fax No 021-58480136
Website www.shyndec.com
Email shyndec@sinopharm.com;xd_zhengquanban@sinopharm.com
Company Address
Register: 上海市浦东新区建陆路378号
Office: 上海市浦东新区建陆路378号
Listing Date 16/06/2004
Shares Capital
Shares Capital: 1,341,172,692
Total A Share: 1,341,172,692
Listed A Share: 1,341,172,692
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.808
DPS(RMB)* ¥ 0.300
NBV Per Share(RMB)* ¥ 9.845
Market Capitalization(RMB) 15.102B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.